Pharmaceuticals

Vyome

Vyome released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 31.59K, actual EPS USD -0.1439 (forecast EPS USD -0.18)

Vyome Holdings Posts Q1 FY26 Net Loss of $985,521

Vyome released FY2025 Annual Earnings on March 18 (EST), actual revenue USD 319.71 K (forecast USD 249 K), actual EPS USD -4.7479 (forecast USD -3.17)

Vyome released FY2025 Q4 earnings on March 18 (EST), actual revenue USD 36.55K (forecast USD 0), actual EPS USD -0.2081 (forecast USD -0.34)

Vyome released FY2025 9 Months Earnings on November 14 During-Market EST, Actual Revenue: USD 283.16K, Actual EPS: USD -3.0574

Vyome released FY2025 Q3 earnings during market hours on November 14 (EST), actual revenue USD 34.63 K (forecast USD 0), actual EPS USD -3.0574 (forecast USD -0.11)

Vyome to release FY2025 Q3 earnings report on November 20 During-Market EST, forecast EPS USD -0.11

Vyome Holdings Inc Acquires MIT AI Spinoff Oculo Health

Vyome released FY2025 Q2 earnings on September 2, 2025 (EST) with actual revenue of USD 49.95 K and EPS of USD 0

Vyome released FY2025 Semi-Annual Earnings on September 2 (EST), actual revenue USD 248.54K, actual EPS USD 0

Vyome released FY2024 Q2 earnings on September 2, 2025 (EST), with actual revenue of USD 34.01K and EPS of USD -0.246

Vyome released FY2024 9 Months Earnings on September 2, 2025 (EST), with actual revenue of USD 195.52K and EPS of USD 0

Vyome Holdings Inc revises equity allocation agreement to raise funding to $12 million

Vyome Holdings Completes Merger with Vyome Therapeutics

Vyome released FY2024 Q1 earnings on May 28 (EST), actual revenue USD 76.98 K, actual EPS USD -0.0672

Vyome released FY2025 Q1 earnings on May 28 (EST), actual revenue USD 198.58K, actual EPS USD 0

Vyome released FY2023 Annual Earnings on April 29, 2025 (EST), with actual revenue of USD 415.94 K and EPS of USD -0.4225

Vyome released FY2023 Q4 earnings on April 29 (EST), actual revenue USD 69.37 K, actual EPS USD 0

Vyome released FY2024 Annual Earnings on April 29 (EST), actual revenue USD 256.94K, actual EPS USD 0

Vyome released FY2024 Q4 earnings on April 29 (EST), actual revenue USD 61.43 K, actual EPS USD 0

Agape ATP

Liminatus Pharma

Sunshine Biopharma

Wheeler Real Estate

NewGenIvf

Quantum Cyber NV

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Infleqtion

HIND

Earnings Watch

Vyome | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 31.59 K

Vyome | 10-K: FY2025 Revenue Beats Estimate at USD 319.71 K

SBIO

LABU

Jason McCarthy from Maxim Group has maintained a Buy rating on Vyome Holdings with a price target of $15.00. He cites strong Phase 2 data for VT-1953, a topical gel for malignant fungating wounds, and the upcoming pivotal Phase 3 trial as key factors. The drug addresses a significant market opportunity exceeding $2B, and Vyome's financial position supports operations into mid-2027. McCarthy views the shares as undervalued given the program's de-risked outlook and upcoming catalysts.

Tip Ranks

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Aprea Therapeutics

Moleculin Biotech

Plus Therapeutics

Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market

ARKG

In Thursday's after-market session, several health care stocks experienced notable movements. Gainers included Vyome Holdings (up 11.3% to $2.45), Tiziana Life Sciences (up 11.19% to $1.39), and Lunai Bioworks (up 10.69% to $0.55). Conversely, Precision Optics Corp saw a decline of 14.5% to $3.6, while Modular Medical dropped 13.8% to $0.15. Other notable losers included Zenas BioPharma (down 9.75% to $20.0) and Eupraxia Pharmaceuticals (down 8.91% to $6.24).

benzinga_article

iShares Global Healthcare

iShares US Medical Devices

SPDR S&P Health Equip

Tiziana Life Sciences

Lunai Bioworks

iShares US Pharma

Zenas Biopharma

Eupraxia Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Modular Medical

Precision Optics

VG Health

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

12 Health Care Stocks Moving In Thursday's After-Market Session

RSLS

LABD

Cullen Investment Group LTD. has reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 60.7%, now holding 8,740 shares valued at $744,000. This change was reported in their recent SEC filing. Other institutional investors have also adjusted their positions in the company. Edwards Lifesciences shares opened at $82.71, with a market cap of $48.04 billion. The company reported earnings of $0.58 per share, missing estimates, but revenue increased by 13.3% year-over-year. Analysts have mixed ratings on the stock, with an average target price of $96.14.

Market Beat

Edwards Lifesciences

ReShape Lifesciences

Direxion S&P Biotech Bear 3X

Lifecore Biomedical

Cullen Investment Group LTD. Has $744,000 Holdings in Edwards Lifesciences Corporation $EW

ZYXIQ

Sentynl Therapeutics has partnered with PRG S&T to license Progerinin, an investigational drug for treating Hutchinson-Gilford Progeria Syndrome (HGPS). The drug is currently in a Phase IIA trial, with results expected by mid-2026. Sentynl will gain full rights to Progerinin upon achieving specific milestones. This agreement enhances Sentynl's portfolio aimed at addressing rare diseases, reflecting their commitment to improving the lives of HGPS patients.

Pharmaceutical Technology

ZYNEX INC

Greenwich Lifesciences

Sentynl and PRG partner for Progerinin licence

Supriya Lifescience Publishes Postal Ballot Notice in Newspapers

Supriya Lifescience Publishes Postal Ballot Notice in Newspapers

VYNE

Vyome Holdings' subsidiary, Livechain, has acquired Humanyze for $5.77 million in an all-stock deal, issuing 211.2 million shares to Remus Capital. This acquisition aims to enhance Livechain's position in AI HR analytics by taking control of Humanyze's assets and operations. The deal, approved by Vyome's board, is expected to limit capital exposure while providing growth opportunities for shareholders. Analysts currently rate Vyome's stock (HIND) as a Hold with a $2.00 price target, citing concerns over revenue decline and cash burn, despite some positive updates.

VYNE Therapeutics

Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics

Vyome(HIND.US)

Vyome | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 31.59 K

Vyome | 10-K: FY2025 Revenue Beats Estimate at USD 319.71 K

Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market

12 Health Care Stocks Moving In Thursday's After-Market Session

Cullen Investment Group LTD. Has $744,000 Holdings in Edwards Lifesciences Corporation $EW

Sentynl and PRG partner for Progerinin licence

Supriya Lifescience Publishes Postal Ballot Notice in Newspapers

Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics